Document:

<PAGE>

                                                                   EXHIBIT 10.13

                                LICENSE AGREEMENT

         This Agreement is made effective this 6th day of September, 2000 by and
between Temple University - Of The Commonwealth System of Higher Education, a
corporation organized and existing under the laws of the Commonwealth of
Pennsylvania, having a principal place of business at Broad Street and
Montgomery Avenue, Philadelphia, Pennsylvania and Nutraceutix, Inc., a
corporation organized and existing under the laws of the State of Delaware,
having a principal place of business at 8340 154th Ave. N.E., Redmond,
Washington 98052.

         WHEREAS, Temple University - Of The Commonwealth System of Higher
Education is the owner of the entire interest in United States Patent
Application 09/037,096 and PCT Application PCT/US99/04508; and

         WHEREAS, Nutraceutix, Inc. desires to obtain an exclusive worldwide
license under the aforementioned patent applications, patents and technical
information related thereto, for application thereof to dietary supplements and
pharmaceutical products, including over-the-counter products, prescription
drugs, OTC drugs and generic drugs;

         NOW, THEREFORE, in consideration of the premises and of the covenants
and obligations hereinafter set forth, and intending to be legally bound, the
parties hereby agree as follows:

1.       DEFINITIONS

The following definitions shall apply throughout this Agreement:

         1.1      "AFFILIATE" shall mean each and every business entity
controlling, controlled by or under common control with COMPANY for the purposes
of manufacture, use or sale of LICENSED PRODUCT. For purposes of this definition
"control" shall mean ownership, directly or indirectly, of at least fifty
percent (50%) of the voting stock.

         1.2      "ANNIVERSARY" shall mean an anniversary of the EFFECTIVE DATE.

         1.3      "COMPANY" shall mean Nutraceutix, Inc. and its AFFILIATES.

         1.4      "CONFIDENTIAL INFORMATION" shall mean all information
disclosed or samples supplied by one party to the other pursuant to this
Agreement. However, CONFIDENTIAL INFORMATION shall not include information
which: (i) was known to the receiving party prior to the date of disclosure by
the disclosing party or is developed independently of information received from
the disclosing party by those who have not had access to this information; or
(ii) is lawfully received in good faith at any time by the receiving party from
others lawfully in possession of the same and having the right to disclose the
same; or (iii) is, as of the date of receipt, in the public domain or
subsequently enters the public domain other than by reason of acts or omissions
of the receiving party; or (iv) is required to be disclosed by law, rule of
court or regulation.

         1.5      "EFFECTIVE DATE" shall mean the date first above written as
the effective date of this Agreement.

                                        1

<PAGE>

         1.6      "INVENTOR" shall mean Reza Fassihi of the TEMPLE faculty.

         1.7      "LICENSED PRODUCT" shall mean any PRODUCT the manufacture, use
or sale of which would infringe, induce infringement of, or contribute to the
infringement of at least one VALID CLAIM contained in a patent application
included in PATENT RIGHTS if that VALID CLAIM were contained, instead, in an
issued patent not included in PATENT RIGHTS.

         1.8      "NET SALES" shall mean the gross receipts from the SALE of
LICENSED PRODUCT by COMPANY or by its sublicensees less deductions for: (i)
transportation charges, including insurance, sales and excise taxes and duties
paid; (ii) normal and customary trade, quantity and cash discounts allowed;
(iii) sales commissions; and (iv) allowances on account of rejection or return
by customers.

         1.9      "PATENT RIGHTS" shall mean United States Patent Application
09/037,096 and PCT Application PCT/US99/04508, and any foreign counterparts
thereof, or any continuations, continuations-in-part, divisions, re-issues,
additions, renewals or extensions thereof, and any patents issuing therefrom.

         1.10     "PRODUCT" shall mean: (i) any dietary supplement (as defined
in the 1994 Dietary Supplement and Health Education Act) (referred to herein as
a "SUPPLEMENT"); (ii) any drug which can be purchased by the general public
without a prescription (referred to herein as an "OTC DRUG"); and (iii) any
prescription drug (whether existing at the time of this Agreement or yet to be
discovered). If any item which is classified on the date of this Agreement as a
SUPPLEMENT, an OTC DRUG or a prescription drug, is subsequently reclassified
otherwise, such item shall nevertheless remain a SUPPLEMENT, an OTC DRUG or a
prescription drug (as the case may be) for all purposes under this Agreement.

         1.10     "SALE" shall mean any transaction for which consideration is
received for the sale, lease, license, transfer or other disposition of LICENSED
PRODUCT by COMPANY or by its sublicensees.

         1.11     "TECHNICAL INFORMATION" shall mean any CONFIDENTIAL
INFORMATION of a technical nature relating to LICENSED PRODUCT, which is in the
possession of TEMPLE as of the effective date of this Agreement, and which is
necessary or useful to COMPANY in furtherance of the development, manufacture or
marketing of LICENSED PRODUCT.

         1.12     "TEMPLE" shall mean Temple University - Of The Commonwealth
System of Higher Education.

         1.13     "VALID CLAIM" shall mean a claim of a patent application or
patent, which claim has not expired and has not been held unenforceable,
unpatentable or invalid by unappealable decision of a court or other
governmental agency of competent jurisdiction.

2.       CONFIDENTIALITY

         2.1      CONFIDENTIAL INFORMATION disclosed in documentary form shall
be marked "Confidential." Oral discussions of CONFIDENTIAL INFORMATION shall be

                                        2

<PAGE>

reduced to writing by the disclosing party and a copy marked "Confidential"
provided to the receiving party within thirty (30) days of the disclosure date.

         2.2      The receiving party shall hold all CONFIDENTIAL INFORMATION in
strict confidence for a period of five (5) years from the disclosure date; not
use said CONFIDENTIAL INFORMATION except as provided in this Agreement; and not
disclose, directly or indirectly, said CONFIDENTIAL INFORMATION to others except
with the prior written consent of the disclosing party.

         2.3      The receiving party shall, upon request by the disclosing
party, promptly return all written materials or samples of tangible property
received hereunder, as well as all summaries thereof and notes pertaining
thereto, with the exception that one copy of said written materials may be
retained by the receiving party solely for archival purposes.

         2.4      Notwithstanding any other provision of this Agreement, it is
recognized by COMPANY that TEMPLE, through the INVENTOR, shall have the right to
publish the results of research concerning LICENSED PRODUCT. However, TEMPLE and
the INVENTOR agree to notify COMPANY in writing of any such proposed publication
ninety (90) days before submission. COMPANY may request deletion of sensitive
information from the proposed publication, and TEMPLE agrees to give good faith
consideration to such a request.

         2.5      The parties shall keep the financial terms of this Agreement
set forth in Section 4 confidential, except to the extent disclosure thereof may
be required by applicable securities laws or otherwise by law. The parties shall
be free to disclose to third parties the existence of this Agreement and the
nonfinancial terms of this Agreement.

         2.6      Promptly after the execution of this Agreement TEMPLE shall
deliver all currently existing TECHNICAL INFORMATION to COMPANY. Thereafter
TEMPLE shall deliver to COMPANY all additional TECHNICAL INFORMATION promptly
after it is developed or obtained by TEMPLE. In addition, TEMPLE shall deliver
to COMPANY from time to time other data, materials and information relating to
the LICENSED PATENT which it develops or obtains and which is necessary or
useful to COMPANY in furtherance of the development, manufacture or marketing of
LICENSED PRODUCT.

3.       GRANT OF LICENSE

         3.1      TEMPLE grants to COMPANY a world-wide exclusive license under
PATENT RIGHTS and TECHNICAL INFORMATION, with the right to grant sublicenses, to
make, have made, use, sell, offer for sale, export, import and otherwise deal
with LICENSED PRODUCT. This license shall be perpetual unless and until
terminated, in whole or in part, in accordance with the provisions of this
Agreement.

         3.2      Notwithstanding the preceding license grant, TEMPLE shall
retain rights to make, have made, use and import LICENSED PRODUCT royalty-free
for non-commercial educational and research purposes only, and shall be free to
grant these rights to other non-profit educational and research institutions.

                                        3

<PAGE>

         3.3      The parties acknowledge that inventions in PATENT RIGHTS may
have resulted from United States Government funding, and agree that their rights
and obligations under this Agreement shall be subject to TEMPLE's obligations to
the United States Government, if any, which arise out of the receipt by TEMPLE
of research funding from the United States Government. In particular, COMPANY
agrees that LICENSED PRODUCT sold in the United States under this Agreement
shall be manufactured substantially in the United States.

4.       PAYMENTS

         4.1      In consideration of the license granted to COMPANY under the
terms of this Agreement, COMPANY shall pay to TEMPLE royalties as follows:

                  (a)      a royalty of [*] for each one thousand (1,000)
tablets of LICENSED PRODUCT which is a SUPPLEMENT and which is sold by COMPANY
or by its sub-licensees; and

                  (b)      a royalty of [*] for each one thousand (1,000)
tablets of LICENSED PRODUCT which is an OTC DRUG which is sold by COMPANY or by
its sublicensees; and

                  (c)      a royalty equal to [*] of NET SALES of any LICENSED
PRODUCT which is a prescription drug and which is sold by COMPANY or by its
sublicensees.

         4.2      In further consideration of the license granted to COMPANY
under the terms of this Agreement, COMPANY shall pay to TEMPLE, within thirty
(30) days after the EFFECTIVE DATE, a non-refundable license fee of [*], which
license fee payment shall not be creditable against any other payments due to
TEMPLE under this Agreement.

         4.3      In further consideration of the license granted to COMPANY
under the terms of this Agreement, COMPANY shall pay to TEMPLE, within thirty
(30) days of the first ANNIVERSARY and annually thereafter, a non-refundable
license maintenance fee regardless of or irrespective of actual NET SALES, which
license maintenance fee payment may be credited against payments due to TEMPLE
under Paragraph 4.1 during the same calendar year, with no carry-over of unused
credit to subsequent calendar years. The amount of the license maintenance fee
payment shall be [*], no more than one half (1/2) of which may be credited
against payments due to TEMPLE under Sub-paragraphs 4.1(a) and 4.1(b) pertaining
to SUPPLEMENTS and OTC DRUGS, and no more than, one half (1/2) of which may be
credited against payments due to TEMPLE under Subparagraph 4.1(c) pertaining to
prescription drugs.

         4.4      In further consideration of the license granted to COMPANY
under the terms of this Agreement, COMPANY shall pay TEMPLE a royalty equal to
[*] of any license fee or similar payment received by COMPANY from any
sub-licensee under the LICENSE in consideration of entering into such
sub-license, not including (i) any royalty or fee received by COMPANY on account
of SALES of LICENSED PRODUCTS or (ii) any payment received by COMPANY as
reimbursement for research and/or development costs; provided that, after
payment of the first royalty pursuant to this Paragraph 4.4, each subsequent
royalty

*Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                        4

<PAGE>

pursuant to this Paragraph 4.4 shall be reduced by an amount equal to COMPANY'S
reasonable, unreimbursed, out-of-pocket research and/or development costs
incurred in connection with developing Licensed Products, which costs include,
and are not limited to: (i) cost of formulation development, (ii) purchase price
of raw materials, including active ingredients, for formulation development,
(iii) labor costs for research and/or development of a Licensed Product, (iv)
cost of research and development compliance and documentation for the U.S. Food
and Drug Administration or similar governmental agencies, (v) cost of creating
pilot batches for bench testing (i.e., for testing friability, hardness, blend
uniformity, etc.), (vi) cost of dissolution testing, (vii) cost of pilot
stability testing according to ICH guidelines, (viii) cost of development and
validation of analytic methods, (ix) cost of development of master formulation
documentation, (x) cost of development of indented bill of materials, (xi) cost
of vendor certification for all raw materials, (xii) cost of cGMP audits of
manufacturing sites, (xiii) cost of bioequivalence and clinical trials, (xiv)
cost of preparing technical files for sale or license to a pharmaceutical
licensee and (xv) costs incurred for subcontractors involved in developing
Licensed Products.

         4.5      Royalty payments pursuant to paragraph 4.1 for SALES in each
country will commence with the first unit of LICENSED PRODUCT sold by COMPANY or
by its sublicensees in such country and will end coincident with the expiration
date of the last-to-expire issued patent within PATENT RIGHTS in such country
covering such LICENSED PRODUCT.

5.       STATEMENTS AND REMITTANCES

         5.1      COMPANY shall keep and shall require its sublicensees to keep
complete and adequate records relating to the manufacture and SALE of LICENSED
PRODUCT.

         5.2      Within sixty (60) days after the close of each calendar
quarter, COMPANY shall remit to TEMPLE a statement of NET SALES by COMPANY and
by its sublicensees on account for such quarter, which statement shall be
accompanied by the payment clue to TEMPLE pursuant to paragraph 4.1 on account
of NET SALES for such quarter.

         5.3      COMPANY shall use commercially reasonable efforts to obtain
from each of its sublicensees verified, and if available audited, financial
statements setting forth the amount of sales of LICENSED PRODUCT by each such
sublicensee ("Sublicensee Reports"). The financial statements of COMPANY and the
Sublicensee Reports will be audited annually by an independent certified public
accountant. TEMPLE shall have the right to employ, at its own expense, a
qualified accountant of its own selection to whom COMPANY shall make no
unreasonable objection, to examine the Sublicensee Reports and the books and
records of COMPANY relating to sales of LICENSED PRODUCT by COMPANY for the
purpose of verifying the amount of royalty payments due. Such examination of the
Sublicensee Reports and the books and records of COMPANY shall take place during
regular business hours during the term of this Agreement and for two (2) years
after its termination, provided however, that such an examination shall not take
place more than once a year and shall not cover records for more than the
preceding three (3) years, and provided that such accountant shall report to
TEMPLE only as to the accuracy of the royalty statements and payments. If such
accountant shall find an underpayment to TEMPLE, presentation of a written
statement substantiating the underpayment will be provided to COMPANY. If the
discrepancy relates to information contained in a Sublicensee Report, COMPANY
shall use commercially reasonable efforts to arrange for an

                                        5

<PAGE>

audit of the subject sublicensee by TEMPLE. If COMPANY is not in agreement with
the findings of the qualified accountant selected by TEMPLE, then COMPANY shall
so notify TEMPLE in writing within thirty (30) days of receipt by COMPANY of
said findings (or in the case of an audit of a sublicensee, within thirty (30)
days of receipt by COMPANY of the findings regarding the audit of the
sublicensee), in which case the parties will jointly appoint, within a further
period of thirty (30) days, an independent qualified accountant to validate, at
COMPANY's expense, TEMPLE's accountant's findings, and the decision of said
independent accountant shall be final. If said independent accountant verifies
that an underpayment has occurred, the amount due and interest (accruing at the
prevailing Prime Rate from the date payment was due through the date of actual
payment to TEMPLE) shall be paid to TEMPLE within thirty (30) days. Should such
underpayment represent more than five percent (5%) of the royalties due TEMPLE,
COMPANY shall reimburse TEMPLE for the cost of the examination by TEMPLE's
accountant which disclosed such underpayment.

         5.4      All payments due to TEMPLE under this Agreement shall be made
in United States dollars and shall be sent by COMPANY to TEMPLE to the attention
of "Business Manager" at the address shown in Paragraph 13.5. However, TEMPLE
shall have the right, upon giving written notice to COMPANY, to receive royalty
payments within a particular country in the local currency if permitted by law.

         5.5      If COMPANY fails to make any payment due to TEMPLE within the
time prescribed by the terns of this Agreement, a penalty equal to one percent
(1%) of the amount due and unpaid on the first day of each calendar month shall
added to the amount due. However, the provisions of this Paragraph 5.5 shall not
apply to any underpayment of royalties which is uncovered, by an audit of the
books of COMPANY or of its sublicensees pursuant to paragraph 5.2.

6.       REPRESENTATIONS

         6.1      TEMPLE represents that it has the right to enter into this
Agreement and to make the herein grant of license under PATENT RIGHTS and
TECHNICAL INFORMATION. TEMPLE further represents that it is the sole and
exclusive owner of PATENT RIGHTS and TECHNICAL INFORMATION, all of which are
free and clear of any lien, charges and encumbrances.

         6.2      TEMPLE makes no warranty that exercise by COMPANY or its
sublicensees of the rights granted herein will not infringe any patents owned by
a third party, or that any patent application within PATENT RIGHTS will issue as
a patent.

         6.3      COMPANY warrants that, prior to the execution of this
Agreement, it has not negotiated or in any manner discussed, whether formally or
informally, with any third party any agreement or other arrangement, including
but not limited to research or consulting agreements, which provides for any
portion of the amounts payable to TEMPLE pursuant to Section 4 of this
Agreement, or any consideration which would reduce the amounts payable to TEMPLE
pursuant to Section 4 of this Agreement, to be paid in any form, including but
not limited to amounts of money or shares of stock, to any INVENTOR, any
INVENTOR's spouse or other relative, or any entity in which any of them has a
financial interest.

                                       6

<PAGE>

7.       PATENT PROSECUTION AND LITIGATION

         7.1      TEMPLE, in consultation with COMPANY but in TEMPLE's sole
discretion, shall diligently prosecute all patent applications and maintain all
patents within PATENT RIGHTS, to the extent permitted by law, in all countries
designated in writing by COMPANY during the term of this Agreement. Except as
provided in paragraph 7.3, COMPANY shall be responsible for all costs and
expenses incurred by TEMPLE, both prior to and during the term of this
Agreement, in the preparation, filing and prosecution of all patent applications
within PATENT RIGHTS, and in the maintenance of all patents within PATENT
RIGHTS. Such costs and expenses shall not be creditable against any other
payments due to TEMPLE under this Agreement.

         7.2      COMPANY shall make all payments due to TEMPLE pursuant to
Paragraph 7.1 within thirty (30) days of receipt of detailed invoices therefore
supported by copies of the subject receipts and invoices or such other
supporting documentation as COMPANY may reasonably request. TEMPLE, in its sole
discretion, may elect to have its patent counsel submit such invoices directly
to COMPANY, in which case COMPANY shall pay TEMPLE's patent counsel directly.

         7.3      In the event COMPANY notifies TEMPLE in writing that it will
stop paying the costs and expenses with respect to any patent application or
patent in any country, TEMPLE, at its option, may assume the obligation of
supporting such patent application or patent in such country, and COMPANY's
rights and obligations thereto under this Agreement shall terminate in such
country. Termination of COMPANY's rights and obligations with respect to any
patent application or patent in any country shall in no way affect the rights
and obligations of COMPANY to the same patent application or patent in any other
country.

         7.4      TEMPLE may file patent applications in countries other than
those designated by COMPANY provided, however that TEMPLE shall notify COMPANY
in writing of any such filing within thirty (30) days of the filing date. If
within thirty (30) days of its receipt of such notification COMPANY fails to
inform TEMPLE in writing that it wishes to support such applications in such
countries, TEMPLE shall bear all the costs associated with such additional
patent application filings, and such applications in such countries and any
patents granting therefrom shall not be included within PATENT RIGHTS. TEMPLE
shall then be free to license such patents and patent applications in such
countries to others.

         7.5      COMPANY, at its option, may defend any claim, made by others,
of patent infringement resulting from the manufacture, use, sale or other
disposition of LICENSED PRODUCT, whether such claim shall be made against TEMPLE
or COMPANY, and if COMPANY defends such claim, COMPANY shall bear all costs and
expenses, including reasonable attorneys' fees, incurred in connection with any
such claim. These costs and expenses will be a credit against fifty percent
(50%) of royalty payments due to TEMPLE on account of NET SALES of said LICENSED
PRODUCT, pursuant to Paragraph 4.1, in each year during the term of this
Agreement until fully offset. Each party to this Agreement agrees that it shall
notify the other party in writing in the event any claim of infringement is made
against that party.

                                        7

<PAGE>

         7.6      In the event either party becomes aware of any actual or
threatened infringement of PATENT RIGHTS in any country, that party shall
promptly notify the other party in writing. COMPANY shall have the first right
to bring an infringement action against the infringer and to use TEMPLE's name
if legally required in connection therewith. If COMPANY does not proceed with a
particular patent infringement action or attempt to sublicense the infringer
within ninety (90) days of notification, TEMPLE, after notifying COMPANY in
writing, shall be entitled to proceed against such infringement at its own
expense, through counsel of its choice. The party conducting such suit shall
have full control over its conduct. In any event, TEMPLE and COMPANY shall
assist one another and cooperate in any such litigation. TEMPLE and COMPANY may
also jointly participate in any infringement action if both parties agree to do
so in writing in advance, and set forth the basis for sharing of expenses.

         7.7      The amount of any recovery resulting from any litigation to
enforce the PATENT RIGHTS or settlement thereof ("Recovery") shall first satisfy
the attorney's fees and costs incurred by the enforcing party in such litigation
("Fees and Costs") provided, however, that if COMPANY is the enforcing party and
a royalty reduction was applied pursuant to Paragraph 7.5 ("Royalty Reduction"),
then TEMPLE shall receive from the Recovery an amount calculated by dividing the
Royalty Reduction by the Fees and Costs and multiplying the result by the
Recovery. Any Recovery in excess of Fees and Costs shall first satisfy royalty
payments due to TEMPLE, with any remaining balance to the enforcing party. Each
party shall always have the right to be represented by counsel of its choice and
at its own expense in any suit instituted by another for infringement. If the
parties have agreed to participate jointly in an infringement action, any
recovery in excess of satisfying the parties' attorney fees, costs of the
litigation and payment of the royalty due to TEMPLE on account of the
infringement, shall be allocated to the parties in the same proportion as the
sharing of the litigation expenses.

8.       INDEMNIFICATION

         8.1      COMPANY agrees to indemnify, hold harmless, and defend TEMPLE,
its trustees, officers, employees and agents against any and all claims,
excluding claims stemming from TEMPLE's use of LICENSED PRODUCT as outlined in
Paragraph 3.2, including fees and costs arising out of the exercise of any
rights granted under this Agreement, without limiting the generality of the
foregoing, against any damages, losses or liabilities whatsoever including but
not limited to death or injury to person or damage to property arising from the
commercial sale and clinical research of LICENSED PRODUCT by COMPANY, its
sub-licensees or any customers of any of them in any manner whatsoever. TEMPLE
shall give COMPANY written notice of any claim(s) related to LICENSED PRODUCT
within thirty (30) days, and TEMPLE shall reasonably cooperate with COMPANY and
its insurance carrier in the defense of any such claim(s).

         8.2      In addition to the foregoing, COMPANY shall maintain, during
the period that any LICENSED PRODUCT is sold or otherwise made available to
others pursuant to this Agreement, Commercial Liability Insurance, including
Product Liability Insurance, with a reputable and financially secure insurance
carriers) to cover the activities of COMPANY and its sub-licensees, if any,
contemplated by this Agreement for minimum limits of two million dollars
($2,000,000.00) per occurrence. Such insurance shall name TEMPLE, its trustees,
officers, employees, and agents as additional insureds. COMPANY shall furnish a
Certificate of

                                        8

<PAGE>

Insurance, upon request, evidencing coverage of two million dollars
($2,000,000.00) with thirty (30) days of written notice of cancellation or
material change to TEMPLE. COMPANY's insurance shall be written to cover claims
incurred, discovered, manifested, or made during the term, or after the
expiration, of this Agreement. COMPANY shall at all times comply, through
insurance or self-insurance, with all statutory workers' compensation and
employers' liability requirements covering any and all employees with respect to
activities performed under this Agreement.

9.       SUBLICENSES

         9.1      COMPANY shall have the right to enter into sublicense
agreements, provided that all applicable material terms of this Agreement are
incorporated into such sublicense agreements to provide for the protection of
TEMPLE and its trustees, officers, employees and agents, and provided further
that each sublicensee is required to carry appropriate insurance and indemnify
TEMPLE and COMPANY for claims arising from breach of the sublicense or such
sublicensee's products, and provided further that COMPANY remains primarily
liable for its obligations under this Agreement. A copy of any sublicense
agreement shall be provided to TEMPLE for its review and approval prior to
execution, which approval shall not be unreasonably withheld or delayed. In the
event Temple fails to deliver to COMPANY a written response to a request for
approval of a sublicense under this Agreement within thirty (30) days of the
date of the request, the subject sublicense shall be automatically approved for
all purposes under this Agreement.

10.      ASSIGNMENT

         10.1     Neither party may assign this Agreement, in whole or in part,
without the written consent of the other, except if such assignment occurs in
connection with the sale of all or substantially all of the business and assets
of the assigning party.

11.      TERMINATION

         11.1     This Agreement may be terminated with respect to any patent
application or patent in any country at any time by mutual written consent of
the parties.

         11.2     COMPANY may, in COMPANY's sole discretion and for any reason
whatsoever, terminate this Agreement in its entirety or only with respect to any
patent application or patent within PATENT RIGHTS in any country by giving
TEMPLE ninety (90) days prior written notification thereof. In addition, COMPANY
may terminate this Agreement by giving TEMPLE sixty (60) days prior written
notice upon material breach by TEMPLE of any material provision of this
Agreement, unless such breach is cured within the period of such notice.

         11.3     TEMPLE may terminate this Agreement by giving COMPANY three
(3) months prior written notice upon material breach of any material provision
of this Agreement by COMPANY, unless such breach is cured within the period of
such notice. However, the notice period shall be only thirty (30) days for any
breach by COMPANY for non-payment of moneys due TEMPLE under this Agreement.

                                        9

<PAGE>

         11.4     This Agreement shall immediately terminate, without notice, if
COMPANY breaches the same material provision of this Agreement three (3) times
in the same calendar year, without regard to whether a cure was effected.

         11.5     This Agreement shall immediately terminate if either party is
adjudicated bankrupt, files a voluntary petition in bankruptcy, makes or
executes an assignment for the benefit of creditors, is liquidated or dissolved,
or a receiver, trustee, liquidator, sequestrator or other judicial
representative is appointed for either party or its property. In such event,
that party shall execute any documents that are necessary to assign or transfer
all interests granted hereunder.

         11.6     Upon termination of this Agreement, TEMPLE shall have the
right to retain any amounts already paid by COMPANY under this Agreement, and
COMPANY shall pay to TEMPLE all amounts accrued which are then due or which
become due based on the SALE of LICENSED PRODUCT, manufactured or produced prior
to the effective date of termination.

         11.7     The provisions of Article 2 (entitled CONFIDENTIALITY) and
Article 8 (entitled INDEMNIFICATION) shall survive the termination of this
Agreement.

12.      PATENT MARKING

         12.1     COMPANY agrees to mark or have marked all LICENSED PRODUCT
sold by COMPANY or by its sub-licensees under this Agreement in accordance with
the statutes of the United States and countries and territories relating to the
marketing of patented articles in which any LICENSED PRODUCT covered by a
granted patent is marketed.

13.      MISCELLANEOUS

         13.1     This Agreement shall be construed and the respective rights of
the parties hereto determined according to the substantive laws of the
Commonwealth of Pennsylvania notwithstanding the provisions governing conflict
of laws under such Pennsylvania law to the contrary. The parties agree that any
dispute arising out of this Agreement may be resolved by recourse to the courts
of the Commonwealth of Pennsylvania or the United States District Court for the
Eastern District of Pennsylvania.

         13.2     If any provision of this Agreement is held to be invalid or
unenforceable under the laws of any jurisdiction of the parties, all other
provisions shall, nevertheless continue in full force and effect.

         13.3     This Agreement constitutes the entire agreement among the
parties pertaining to LICENSED PATENT and supersedes all previous arrangements,
whether written or oral. Any amendment or modification to this Agreement shall
be made in writing signed by both parties.

         13.4     Time is of the essence under this Agreement.

         13.5     Notices and payments to the parties shall be addressed as
follows:

                  To TEMPLE:             Office of Technology Transfer

                                       10

<PAGE>

                                         Temple University (083-45)
                                         1601 North Broad Street, Room 406
                                         Philadelphia, Pennsylvania 19122-6099

                  To COMPANY:            Nutraceutix, Inc,
                                         Attention: President
                                         8340 154th Ave. N.E.
                                         Redmond, WA 98052

         Either party may change its address for notice by giving notice to the
other in the manner herein provided. Any notice required or provided for by the
terms of this Agreement shall be in writing and sent by registered or certified
mail, return receipt requested, postage prepaid and properly addressed in
accordance with the paragraph above. The effective date of notice shall be the
actual date of receipt.

         IN WITNESS WHEREOF, the parties have caused this Agreement to be
executed by their duly authorized representatives as of the date first above
written.

         For Temple University - Of The Commonwealth System of Higher Education:

         BY /s/                                                  DATE __________
            --------------------------------------------------
         Martin S. Dorph
         Vice President, Chief Financial Officer and Treasurer

         For Nutraceutix, Inc.:

         BY /s/                                                   DATE _________
            ---------------------------------------------------
         David T. Howard
         President & CEO

                                       11<PAGE>

                                                                   EXHIBIT 10.14

                    MASTER RESEARCH AND DEVELOPMENT AGREEMENT

This Agreement is made effective this first day of May, 2001 by and between
Temple University - Of The Commonwealth System of Higher Education, having a
principal place of business at Broad Street and Montgomery Avenue, Philadelphia,
Pennsylvania (hereinafter referred to as "Temple") and Nutraceutix, Inc., having
a principal place of business at 8340 154th Avenue NE Redmond, Washington
98052-3864(hereinafter referred to as "Company").

WHEREAS, the parties have entered into a License Agreement effective September
6, 2000 (hereinafter referred to as the "License") pertaining to Temple's U.S.
Patent Number 6,090,411 issued July, 18, 2000;

WHEREAS, Company wishes that Temple perform certain testing and/or research of
interest to Company in connection with the development of dietary supplement,
over-the-counter or prescription products, and wishes to obtain the results of
the aforementioned testing and/or research; and

WHEREAS, Temple wishes to undertake the aforementioned testing and/or research
and to publish the results thereof without jeopardizing the confidentiality of
Company's confidential information;

NOW, THEREFORE, in consideration of the premises and of the covenants and
obligations hereinafter set forth, the parties, intending to be legally bound,
agree as follows:

                             ARTICLE I - DEFINITIONS

1.1  "Project" shall mean an individual testing and/or research project under
     this Agreement, the scope, duration and additional costs of which are
     described in an exhibit that is attached to this Agreement by mutual
     written consent of the parties.

1.2  "Project Period" shall mean the period of performance of a Project, which
     shall terminate on the earlier of (i) the date specified in the
     corresponding exhibit to this Agreement or (ii) the date on which Company
     notifies Temple in writing that it accepts the Project Results therefor.

1.3  "Project Cost" shall mean the amount of money, if any, to be paid by
     Company to Temple to carry out each Project, as specified in the
     corresponding exhibit to this Agreement.

1.4  "Project Results" shall mean discoveries, inventions, know-how, testing
     data, methods, techniques and other information, patentable or
     unpatentable, resulting from Company's funding of any Project during the
     term of this Agreement.

1.5  "Patentable Results" shall mean Project Results that Temple deems, in its
     sole discretion, to be patentable and for which Temple files a United
     States patent application within six (6) months of the end of the
     corresponding Project Period.

                                       1

<PAGE>

1.6  "Improvement Patents" shall mean United States patent applications filed by
     Temple for Patentable Results covered by at least one claim of a patent
     application or patent previously under the License, and any foreign
     counterparts thereof, or any continuations, continuations-in-part,
     divisions, re-issues, additions, renewals or extensions thereof, and any
     patents issuing therefrom.

1.7  "New Patents" shall mean United States patent applications filed by Temple
     for Patentable Results not covered by any claim of a patent application or
     patent previously under the License, and any foreign counterparts thereof,
     or any continuations, continuations-in-part, divisions, re-issues,
     additions, renewals or extensions thereof, and any patents issuing
     therefrom.

1.8  "Principal Investigator" shall mean Dr. Reza Fassihi, designated by Temple
     to direct the Projects and to serve as the contact person for Company on
     all technical matters relating to the Projects.

1.9  "Confidential Information" shall mean all information disclosed and any
     tangible property pertaining thereto supplied by one party to the other.
     Any information disclosed in writing shall be deemed Confidential
     Information only if marked "Confidential." Any information disclosed orally
     shall be deemed Confidential Information only if reduced to writing and a
     copy marked "Confidential" is provided to the receiving party within thirty
     (30) days of the date of oral disclosure. However, Confidential Information
     shall not include information that: (i) was known to the receiving party
     prior to the date of the disclosure by the other party; or (ii) is lawfully
     received in good faith at any time by the receiving party from a third
     party lawfully in possession of the same and having the right to disclose
     the same; or (iii) is, as of the date of receipt, in the public domain or
     subsequently enters the public domain other than by reason of acts or
     omissions of receiving party; or (iv) the receiving party is required to
     disclose by law, rule of court or regulation; or (v) is independently
     developed by the receiving party, as evidenced by written records.

                               ARTICLE II - SCOPE

2.1  This Agreement pertains to the development of dietary supplement,
     over-the-counter and prescription products. The scope of the work to be
     performed under each Project shall be described in an exhibit in the form
     attached hereto as Exhibit A that, by mutually written consent, shall be
     attached hereto and incorporated herein by reference, such exhibit to
     specify, for each Project, the scope of the work to be performed, the
     Project Costs, if any, and the Project Period.

2.2  Temple shall make reasonable efforts to complete each Project. However,
     Temple makes no warranties as to the completion of any Project or the
     achievement of any particular goal.

                             ARTICLE III - PAYMENTS

3.1  Company shall pay to Temple the Project Cost for each Project as specified
     in the applicable version of Exhibit A to this Agreement. Unless otherwise
     specified on such document, said

                                        2

<PAGE>

     Project Cost shall be paid in two equal non-refundable payments, the first
     due within thirty (30) days of the start of the Project and the second due
     within thirty (30) days of receipt by Company of Temple's report on Project
     Results for such Project pursuant to Paragraph 4.5 of this Agreement.
     Checks shall be made to "Temple University" (with the name of the Principal
     Investigator shown for reference purposes) and sent to the attention of
     "Business Manager" at the address shown in Paragraph 8.5 of this Agreement.

                      ARTICLE IV - TRANSFER OF INFORMATION

4.1  During the "Confidentiality Period" described at the end of this Paragraph
     4.1, the receiving party shall hold Confidential Information disclosed by
     the other party in strict confidence; shall not use such Confidential
     Information except as permitted herein; and shall not disclose, directly or
     indirectly, such Confidential Information to any third party without the
     prior written consent of the disclosing party. The receiving party shall
     use at least the same degree of care to maintain the other party's
     Confidential Information secret as it uses in maintaining as secret its own
     confidential information, but always at least a reasonable degree of care.
     The receiving party shall restrict disclosure of the other party's
     Confidential Information solely to those of the employees of the receiving
     party having a need to know such Confidential Information in order to
     accomplish the purpose set forth herein. The receiving party shall also
     advise its employees before they have access to the other party's
     Confidential Information, of the obligations of the receiving party
     hereunder, and require such employees to maintain those obligations. For
     purposes of this Paragraph 4.1, the Confidentiality Period shall be a
     period of five (5) years from the date of disclosure of the Confidential
     Information, provided that if the disclosing party notifies the receiving
     party in writing prior to the end of that five (5) year period that it
     wishes to extend the Confidentiality Period with respect to a particular
     item or items of Confidential Information, the Confidentiality Period with
     respect to the item(s) of Confidential Information so identified shall be
     extended until the date specified by the disclosing party in its written
     notification.

4.2  Upon request by the disclosing party, the other party shall promptly return
     all written materials or samples of tangible property received hereunder,
     with the exception that one copy of written materials may be retained by
     the other party solely for archival purposes. In the alternative, upon the
     disclosing party's request, the other party shall return or destroy all
     materials and confirm such destruction in writing.

4.3  Temple shall provide to Company a copy of any proposed publication or other
     disclosure, written or oral, containing Project Results, at least sixty
     (60) days before the date of submission of such proposed publication or
     other disclosure, for comment by Company. During the aforementioned sixty
     (60) day period, Company may request in writing that its Confidential
     Information be removed from the proposed publication or other disclosure,
     and Temple agrees to comply. Further, (i) if the proposed publication or
     other disclosure concerns Project Results owned by Company pursuant to
     Paragraph 5.1, Temple shall remove from the proposed publication or other
     disclosure such information concerning the Project Results as Company may
     specify during such sixty (60) day period, and (ii) if the proposed
     publication or other disclosure concerns Project Results owned by Temple
     pursuant to Paragraph 5.2 and Company requests, during said sixty (60) day
     period, that Temple file a

                                        3

<PAGE>

     patent application with respect to the subject Project Results, Temple
     shall file a patent application with respect to the subject Project Results
     prior to making the proposed publication or other disclosure.

4.4  The Principal Investigator shall submit to Company a report on Project
     Results within thirty (30) days of the end of the corresponding Project
     Period.

                          ARTICLE V - OWNERSHIP RIGHTS

5.1  Subject to the provisions of Paragraph 4.3 of this Agreement, title to
     Project Results other than Patentable Results shall belong exclusively to
     Company. Temple shall not disclose Project Results owned by Company to any
     third party without Company's prior written consent. The foregoing
     prohibition on disclosure applies to oral disclosures as well as disclosure
     in written or computer-readable form or through utilization of technology.

5.2  Title to Patentable Results shall belong exclusively to Temple and Temple
     shall have the exclusive right to procure patents therefor provided that if
     Temple fails to file a patent application for any such Patentable Result
     within six (6) months after the end of the applicable Project Period, title
     to such Patentable Result shall thereafter belong exclusively to Company.
     In the event Temple files such a patent application, Temple shall so notify
     Company in writing within thirty (30) days of the filing date.

                     ARTICLE VI - LICENSE AND OPTION RIGHTS

6.1  Company shall have the option to add to the License any Improvement Patent
     that is not already under the License provided that such option is
     exercised in writing within thirty (30) days of receipt by Company of
     Temple's notice pursuant to Paragraph 5.2. Company shall make the royalty
     payments specified in Paragraphs 4.1 and 4.3 of the License with respect to
     any Improvement Patent added to the License pursuant to this Paragraph 6.1,
     but shall not be required to pay the license fee specified in Paragraph 4.2
     of the License with respect to any Improvement Patent.

6.2  Company shall have the option to add to the License any New Patent that is
     not already under the License provided that such option is exercised in
     writing within three (3) months of the end of the Project. Company shall
     make the royalty payments specified in Paragraphs 4.1 and 4.3 of the
     License with respect to any New Patent added to the License pursuant to
     this Paragraph 6.2. In addition, Company shall pay, as specified in
     Paragraph 4.2 of the License, a non-refundable license fee of [*] for each
     New Patent added to the License, and the payment shall not be creditable
     against any other payments due to Temple under the License.

6.3  In further consideration of Temple's work on Projects, any product making
     use of Project Results owned by Company pursuant to Article 5 of this
     Agreement, notwithstanding any provisions to the contrary in Paragraph 1.10
     and in Article 4 of the License, shall be considered LICENSED PRODUCT under
     the License and shall be subject to royalties payable to Temple at [*] of
     the rate provided in Paragraphs 4.1 and 4.3 of the

*Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       4

<PAGE>

     License, with a royalty payment period of ten (10) years from the date of
     FIRST SALE of such LICENSED PRODUCT.

6.4  Temple shall have an irrevocable, non-exclusive license to practice,
     royalty-free, all Project Results owned by Company for Temple's own
     internal, non-commercial educational and research purposes.

6.5  Company shall be responsible, pursuant to Paragraph 7.1 of the License, for
     all costs and expenses incurred by Temple on account of any patent
     application or patent that is added to the License, which costs and
     expenses are incurred both before and after the date such patent
     application or patent is added to the License. However, if Company wishes
     to add a Patentable Result to LICENSED PRODUCTS under the License but
     believes that obtaining a patent for such Patentable Result is not
     economically justified in light of all relevant business considerations,
     Company may so notify Temple in writing within thirty (30) days of receipt
     by Company of Temple's notice, pursuant to Paragraph 5.2. In the event of
     such notice by Company to Temple, notwithstanding any provisions to the
     contrary in Paragraphs 1.10 and in Article 4 of the License, any product
     derived from such Patentable Result shall be considered LICENSED PRODUCT
     under the License as of the effective date of Company's notice, except that
     for such LICENSED PRODUCT: (i) Company's licensing rights shall be
     non-exclusive, (ii) royalties shall be at one-half (1/2) of the rate
     provided in Paragraph 4.1 of the License, (iii) the royalty payment period
     shall be ten (10) years from the date of FIRST SALE of such LICENSED
     PRODUCT, and (iv) Company shall not be required to pay any patent costs or
     license fees for such patent application, its foreign counterparts, or any
     patents issuing therefrom.

                       ARTICLE VII - TERM AND TERMINATION

7.1  The initial term of this Agreement shall begin on the effective date of
     this Agreement and, unless extended or renewed in writing by both parties,
     shall end on the later of (i) twenty four (24) months from the effective
     date of this Agreement or (ii) the end of any Project Period then in
     effect.

7.2  The terms and conditions of Articles IV, V and VI herein shall survive
     termination of this Agreement.

                          ARTICLE VIII - MISCELLANEOUS

8.1  This Agreement constitutes the entire understanding of the parties with
     respect to the matters herein contained and each acknowledges and agrees
     that, except for the License, there are no warranties, representations or
     understandings between them other than those expressly set forth herein.
     Each party warrants and represents that the terms of this Agreement are not
     inconsistent with any other contractual or legal obligations it may have.
     This Agreement may be modified only by written consent signed by both
     parties.

8.2  The rights and duties of the parties shall be governed by the laws of the
     Commonwealth of Pennsylvania. The parties agree that any dispute arising
     out of this Agreement may be

                                        5

<PAGE>

     resolved by recourse to the courts of the Commonwealth of Pennsylvania or
     the United States District Court for the Eastern District of Pennsylvania.

8.3  If any arbitration, litigation or other legal proceedings relating to this
     Agreement occurs, the prevailing party shall be entitled to recover from
     the other party (in addition to any other relief awarded or granted) its
     reasonable costs and expenses, including attorney's fees, incurred in the
     proceedings.

8.4  This Agreement is binding upon the parties, and upon the directors,
     officers, employees and agents of each.

8.5  Any notice, report, or other communication required hereunder shall be sent
     to the parties at the addresses below:

         To Temple:           Office of Technology Transfer
                              Temple University (083-45)
                              1601 N. Broad Street, Room 406
                              Philadelphia, PA 19122-6099

           To Company:        Nutraceutix, Inc.
                              Attention: David T. Howard
                              8340 154th Avenue NE
                              Redmond, Washington 98052-3864

                                        6

<PAGE>

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by
their duly authorized representatives the day and year written below.

Temple University - Of The Commonwealth System Of Higher Education:

By: /s/                                                Date:____________
    ----------------------------------------
        Martin S. Dorph
        Vice President, Chief Financial Officer and Treasurer

Nutraceutix, Inc.:

By: /s/
    ----------------------------------------           Date:____________
        David T. Howard
        President & CEO

IN ACKNOWLEDGMENT OF HAVING READ UNDERSTOOD THE FOREGOING:

By: /s/
    ----------------------------------------           Date:____________
        Principal Investigator

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]